Farhad Parhami
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$5.6MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $5.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 9, 2026 | NIH | SBIR Phase I Examination of anti-fibrotic and immune modulatory effects of Oxy210 for targeting cystic fibrosis | $365K | Max Biopharma, Inc. |
| May 7, 2024 | NIH | SBIR Phase II Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis | $890K | Max Biopharma, Inc. |
| May 1, 2023 | NIH | SBIR Phase II Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis | $897K | Max Biopharma, Inc. |
| Aug 18, 2022 | NIH | SBIR Phase II Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion | $852K | Max Biopharma, Inc. |
| Aug 10, 2022 | NIH | SBIR Phase I An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling | $318K | Max Biopharma, Inc. |
| May 23, 2022 | NIH | SBIR Phase I Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH | $321K | Max Biopharma, Inc. |
| Sep 1, 2021 | NIH | SBIR Phase II Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion | $1.7M | Max Biopharma, Inc. |
| Aug 21, 2020 | NIH | SBIR Phase I Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH | $224K | Max Biopharma, Inc. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#223
Awards as PI#190
Patents#273
Companies
- Max Biopharma, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.